Tripeptide/Hexapeptide Topical and Hybrid Laser Treatment for Acne Scarring

University of Rochester

Status: Completed

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic

Treatments: Other: Cetaphil face cream; Device: Hybrid fractional laser; Other: Alastin Regenerating Skin Nectar with TriHex Technology

Study type: Interventional

Funder types: Other

Identifiers

NCT04606134

STUDY00003126

Details and patient eligibility

About

To evaluate the efficacy of a tripeptide/hexapeptide topical (Alastin Regenerating Skin Nectar with TriHex Technology®) in wound healing and scar reduction following Erbium:YAG hybrid resurfacing laser for acne scarring compared to the standard of post-procedure care consisting of a bland moisturizer.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• male or females
• age 18 and older
• with evidence of grade II-III acne scars on the face (mild to moderate) as determined by the Goodman & Baron qualitative global acne scar grading system

Exclusion criteria

• treatment to face with any energy device within 6 months
• tanning within 7 days
• dermabrasion or chemical peel within 3 months
• current use of systemic retinoids
• keloidal scaring in the treatment area
• use of systemic steroids within 6 months
• use of topical products with retinoid, alpha-hydroxyacid, salicylic acid, vitamin C or E within 14 days

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

10 participants in 2 patient groups, including a placebo group

Experimental

Experimental group

Treatment:

Device: Hybrid fractional laser

Other: Alastin Regenerating Skin Nectar with TriHex Technology

Control

Placebo Comparator group

Treatment:

Device: Hybrid fractional laser

Other: Cetaphil face cream